{
  "scenario_id": "pharma_drug_approval_investment_2025",
  "context": "Mid-sized pharmaceutical company evaluating major investment in oncology drug development program",
  "stakeholders": {
    "requester": "VP Research & Development",
    "approvers": [
      "CEO",
      "CFO",
      "Chief Medical Officer"
    ],
    "influencers": [
      "Head of Regulatory Affairs",
      "VP Commercial",
      "Clinical Operations Director"
    ]
  },
  "request": {
    "amount": "$450 million",
    "purpose": "Complete Phase 2/3 clinical trials for novel immunotherapy drug",
    "urgency": "high",
    "justification": "Address unmet need in metastatic melanoma with projected market size of $15B by 2030"
  },
  "decision_process": [
    {
      "stage": "initial_scientific_review",
      "duration": "3 weeks",
      "activities": [
        "Preclinical data analysis",
        "Target product profile development",
        "Competitive landscape assessment"
      ],
      "outcome": "Strong scientific foundation confirmed"
    },
    {
      "stage": "financial_and_market_evaluation",
      "duration": "4 weeks",
      "activities": [
        "NPV modeling",
        "Market sizing analysis",
        "Pricing strategy development",
        "Reimbursement pathway assessment"
      ],
      "outcome": "Positive ROI projected with 25% IRR"
    },
    {
      "stage": "regulatory_and_risk_assessment",
      "duration": "2 weeks",
      "activities": [
        "FDA pathway consultation",
        "IP portfolio review",
        "Clinical trial design validation",
        "Risk mitigation planning"
      ],
      "outcome": "Feasible regulatory path with manageable risks"
    },
    {
      "stage": "executive_approval",
      "duration": "1 week",
      "activities": [
        "Board presentation",
        "Final risk discussion",
        "Investment committee vote"
      ],
      "outcome": "Approved with milestone-based funding release"
    }
  ],
  "business_impact": {
    "expected_outcome": "First-in-class therapy capturing 15% market share",
    "projected_value": "$1.8 billion peak annual sales",
    "risk_factors": [
      "Clinical trial failure rate (30%)",
      "Regulatory delays",
      "Manufacturing scalability",
      "Competitor entries"
    ]
  },
  "decision_criteria": [
    "Clinical efficacy data strength",
    "Market opportunity size",
    "Competitive differentiation",
    "Regulatory approval probability",
    "Financial return metrics",
    "Portfolio fit"
  ],
  "outcome": "Approved",
  "lessons_learned": "Early regulatory engagement critical for complex biologics; consider partnership options for risk sharing"
}